BTK Inhibitors in CLL / SLL

Blocking the B-cell receptor (BCR) pathway through oral medications that block it from signaling by inhibiting Bruton’s Tyrosine Kinase or BTK have revolutionized the management of chronic lymphocytic leukemia or CLL. A newer BTK inhibitor (BTKi), pirtobrutinib, offers a potential advantage to CLL patients.

The following short video with animation walks through how all the approved BTKi’s work and how resistance can develop and be overcome.

After watching the video, please take a moment to take a short quiz to test your knowledge.